U.S.S.N. 09/857,332 Filed June 4, 2001 Amendment and Response to First Office Action Page 2



RECEIVED OCT 0.3 2032 TECH CENTER 1800 2900

In the Claims:

Clean Copy of Claims as Amended

Please amend Claims 33, 41, 49, and 57 as follows.

- 33. (Amended) A method of treating cancer comprising:
- (a) administration of a composition comprising *Mycobacterium phlei* (*M.phlei*)-DNA complexed on *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier; and
- (b) administration of a chemotherapeutic agent to an animal or a human having cancer, wherein the composition and the chemotherapeutic agent administered to the animal or the human having cancer display an anti-cancer synergism.
 - 41. (Amended) A method of treating cancer comprising:
- (a) administration of a composition comprising *Mycobacterium phlei* (*M.phlei*)-DNA (M-DNA) and a pharmaceutically acceptable carrier; and
- (b) administration of a chemotherapeutic agent to an animal or a human having cancer, wherein the composition and the chemotherapeutic agent administered to the animal or the human having cancer display an anti-cancer synergism.
 - 49. (Amended) A method of treating cancer comprising:
- (a) administration of a composition comprising a mycobacterial DNA complexed on mycobacterial cell wall (BCC) and a pharmaceutically acceptable carrier; and
- (b) administration of a chemotherapeutic agent to an animal or a human having cancer, wherein the composition and the chemotherapeutic agent administered to the animal or the human having cancer display an anti-cancer synergism.
 - 57. (Amended) A method of treating cancer comprising:
- (a) administration of a composition comprising a mycobacterial DNA (B-DNA) and a pharmaceutically acceptable carrier; and